ViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Serial Monitoring for AAA
Key facts
- Where
- Calgary, Montreal, and Toronto, CanadaSee the 4 sites
Where in Canada
- UCGY - University of Calgary, Peter Lougheed CenterCalgary, CanadaContact: Emi SandersTaking people
- CHUM - Centre Hospitalier de l'Universite de MontrealMontreal, CanadaContact: Jennifer SatterthwaiteTaking people
- MUHC, McGill University Health CentreMontreal, CanadaContact: Marie-Amélie LukaszewskiTaking people
- UHN - University Health Network - Toronto General HospitalToronto, CanadaContact: Naomi EisenbergTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- ViTAA Medical Solutions
- Trial code
- NCT05004051
- Record updated
- 19 September 2025
- Original description
This is a Prospective Registry study to collect imaging and clinical data both on patients with aortic aneurysm disease undergoing serial monitoring and on patients pre and post-endovascular repair, using ViTAA (The Sponsor) aortic mapping technology.Read full original descriptionShow less
Prospective Registry Study to Collect Imaging and Clinical Data on Patients With Aortic Aneurysm Disease Undergoing Serial Monitoring & Pre and Post Endovascular Repair
This is a Prospective Registry study to collect imaging and clinical data both on patients with aortic aneurysm disease undergoing serial monitoring and on patients pre and post-endovascular repair, using ViTAA (The Sponsor) aortic mapping technology.
Inclusion: Patient is aged 18 years or over; Infrarenal Aortic Aneurysm ≥ 45 mm in diameter; Patient meets on-IFU criteria for endovascular reconstruction.
Exclusion: Patients with previous aortic reconstruction in the involved segment; Patients receiving oral or parenteral corticosteroid therapy for other unrelated disease. (Excludes inhaled corticosteroids); Patient has a known or clinically suspected major connective tissue disorder, autoimmune disorder, vasculitis, or aortic dissection; Patient has arrhythmia; Patient has renal failure (defined as dialysis dependent or serum creatinine ≥2.0mg/dL or 175umol/L; Patient has a sensitivity to contrast imaging agents; Patient has aortic dissection; Patient has atrial fibrillation.